Abstract:A key aspect that must be supervised during the development of recombinant therapeutic products is the potential presence of impurities. Residual host cell proteins (HCPs) are a major class of process-related impurities derived from the host organism that even in trace amount have the potential to affect product quality, safety, and efficacy. Therefore, the product purification processes must be optimized to consistently remove as many HCPs as feasible, with the goal of making the product as pure as possible. The workhorse of HCP monitoring and quantitation during bioprocessing manufacturing is sandwich ELISA (enzyme-linked immunosorbent assay), which employs polyclonal anti-HCP antibodies for both capture and detection. Commercial ELISA kits developed from Chinese Hamster Ovary (CHO) cell lines are widely applied in early drug development stages (preclinical, phase I, and phase II), but are not specifically designed for a given manufacturer's proprietary cell line, and users do not have control over reagent availability and lot-to-lot consistency. For later development stages, the upstream process-specific method is preferred to guarantee an improved sensitivity and coverage. In agreement with the USP General Chapter 〈1132〉, a platform assay can be used in place of the commercial one through all stages of product development, if already available when product development starts. This proof-of-concept study was carried out to demonstrate the feasibility and the advantages of the development of a proprietary CHO HCPs platform ELISA. Different proprietary mock materials have been characterized and compared by orthogonal bidimensional electrophoresis techniques (SDS-PAGE coupled to SS/WB and 2D DIGE) with the scope of selecting the best antigen-antibody couple for setting up the in-house ELISA. A preliminary evaluation of the in-house method performance has been done in comparison with the commercial assay, demonstrating that the platform method is promising for an accurate and precise CHO HCPs quantification during the early phase product and process development.

Monitoring Host Cell Protein Contaminant Clearance During Purification of a Recombinant Staphylokinase Variant K35R by Immunological Assay

Purification and Characterization of a Staphylokinase Variant, K35R

[Purification of Fusion Protein HSA/IL1ra and Its Bioactivity].

Establishment and evaluation of detection methods for process‐specific residual host cell protein and residual host cell DNA in biological preparation

A novel approach to monitor clearance of host cell proteins associated with monoclonal antibodies

Host cell protein quantification of an optimized purification method by mass spectrometry

[Preparation and Application of Antibody Against Staphylococcal Enterotoxin C2].

Risk Control of Host Cell Proteins in One Therapeutic Antibody Produced by Concentrated Fed‐batch (CFB) Mode

Establishment of Indirect Competitive Enzyme Linked Immunosorbent Assay for the Detection of Platycodin D in Radix Platycodonis

Identification of protein components and quantitative immunoassay for SEC2 in staphylococcin injection.

Quantitation of Host Cell Proteins by Capillary LC/IMS/MS/MS in Combination with Rapid Digestion on Immobilized Trypsin Column Under Native Conditions

[The Renaturation and Purification of RGD-staphylokinase by Gel Filtration].

Construction and Characterization of Novel Staphylokinase Variants with Antiplatelet Aggregation Activity and Reduced Immunogenecity.

Improved Host Cell Protein Analysis in Monoclonal Antibody Products through Molecular Weight Cutoff Enrichment

Detection and quantitation of host cell proteins in monoclonal antibody drug products using automated sample preparation and data-independent acquisition LC-MS/MS

Development of a sandwich ELISA for the specific quantitation of hemagglutinin (HA)-tagged proteins during their inducible expression in Escherichia coli

Optimized Sample Preparation and Data Processing of Data-Independent Acquisition Methods for the Robust Quantification of Trace-Level Host Cell Protein Impurities in Antibody Drug Products

Technical advancement and practical considerations of LC-MS/MS-based methods for host cell protein identification and quantitation to support process development

In-house CHO HCPs platform: A promising approach for HCPs ELISA monitoring

Purification and Identification of Recombinant Human Granulocyte Colony-Stimulating Factor Muteint (Rhg-Csf-ala-17)

The methods for determining the purity and in vitro or in vivo activity of recombinant human endostatin.